- Home
- RF vs ROIV Comparison
RF vs ROIV Comparison
Compare RF & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RF | ROIV |
|---|---|---|
| Founded | 1970 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1B | 20.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | RF | ROIV |
|---|---|---|
| Price | $28.05 | $28.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 9 |
| Target Price | ★ $29.44 | $28.94 |
| AVG Volume (30 Days) | ★ 8.8M | 4.4M |
| Earning Date | 04-17-2026 | 05-28-2026 |
| Dividend Yield | ★ 3.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,053,000.00 |
| Revenue This Year | $14.98 | N/A |
| Revenue Next Year | $3.82 | $744.61 |
| P/E Ratio | $13.07 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.67 | $10.58 |
| 52 Week High | $31.53 | $30.33 |
Technical Indicators
Market Signals| Indicator | RF | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 53.84 | 50.50 |
| Support Level | $27.70 | $27.00 |
| Resistance Level | $28.06 | $30.26 |
| Average True Range (ATR) | 0.60 | 0.94 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 41.45 | 39.10 |
Price Performance
Historical ComparisonAbout RF Regions Financial Corporation
Regions Financial is one of the midsized regional banks in the US, with around $160 billion in total assets as of Sept. 30, 2025. Headquartered in Birmingham, Alabama, Regions Financial has a footprint mostly in the US southeast. The bank provides a diversified set of financial services in retail banking, commercial banking, card and treasury management, wealth management, and capital markets.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.